Adalimumab

Description

Adalimumab is a medicine used either alone or in a combination with other medicines to relieve the symptoms of conditions where the immune system attacks healthy parts of the body (auto-immune disorders); these symptoms may include pain, swelling, damage to the body structure, etc. It is used for the treatment of conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, uveitis, chronic plaque psoriasis, etc.

Side effects

Major & minor side effects for Adalimumab

  • Injection site redness, bruising, or sores
  • Nausea and Vomiting
  • Headache
  • Back pain
  • Burning, numbness, tingling in the arms and feet
  • Vision disturbances
  • Weakness in arms, hands, legs or feet
  • Chest pain
  • Shortness of breath
  • Skin rash, hives, or itching
  • Swelling of the face, arms, hands, lower legs, or feet
  • Difficulty in swallowing
  • Fever with chills
  • Unusual bleeding or bruising
  • Pale and clammy skin
  • Red, scaly patches or pus-filled bumps on the skin
  • Ear congestion
  • Black or tarry stools
  • Sleep disturbances

Uses of Adalimumab

What is it prescribed for?

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Ulcerative Colitis
  • Chronic plaque psoriasis
  • Hidradenitis suppurativa
  • Uveitis
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time taken by this medicine to show its effect is subject to vary based on the condition being treated and individual constitution.
  • Duration of effect
    The amount of time for which this medicine remains effective in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after assessing the condition and evaluating the risks and benefits associated with the use of this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to adalimumab or any other inactive ingredient present in the formulation.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after assessing the condition and evaluating the risks and benefits associated with the use of this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition.
General warnings

Other medicines

Adalimumab may interact with many other medicines and their interaction may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

Serious infections

Use of this medicine may affect the immune system, making you susceptible to opportunistic infections from a wide variety of pathogens. Use of this medicine is not recommended if you have an active infection. If a serious infection develops, consult your doctor immediately and discontinue the use of this medicine based on the doctor's advice.

Malignancies

Use of this medicine may cause a malignancy or reactivation of a previously treated malignancy. Hence, it should be used with caution and frequent clinical monitoring should be performed, especially for children, adolescents, and young adults. If a malignancy develops, appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition.

Serious allergic reactions

Use of this medicine may cause serious and life-threatening allergic reactions in some people. Discontinue the use of this medicine immediately if any allergic reactions occur.

Hepatitis B virus reactivation

Use of this medicine may increase the risk of reactivation of hepatitis b virus in patients who are chronic carriers. Close clinical monitoring is advised, if the patient is identified as a carrier of the virus, during treatment as well as for several months after the use of this medicine. If the hepatitis B infection is reactivated during treatment, the treatment should be discontinued and appropriate antiviral therapy should be initiated.

Neurological reactions

Use of this medicine may cause neurological problems and exacerbate the symptoms of nervous system disorders. This medicine should be used with caution in patients with a preexisting nervous system disorder like multiple sclerosis, optic neuritis, Guillain-Barre syndrome, etc. Close monitoring of clinical condition, appropriate corrective measures, dose adjustments, or replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Hematological reactions

Use of this medicine may cause blood cell component disorders. Hence, close monitoring of hematological function is advised during treatment with this medicine. Therapy should be stopped if any serious blood cell component abnormality is identified.

Heart failure

Use of this medicine has been associated with worsening of congestive heart failure as well as the new onset of heart failure in some rare cases. Hence, appropriate clinical monitoring is advised during treatment with this medicine. Replacement with a suitable alternative may be necessary in some cases based on the clinical condition.

Autoimmunity

Use of this medicine may result in the formation of autoantibodies and may cause a lupus-like syndrome. Treatment with this medicine should be discontinued immediately in such cases.

Immunization

Use of live vaccines should be avoided while the patient is being treated with this medicine. Special precaution is advised for pediatric patients.

Driving or Operating machinery

Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Missed Dose

Administer the missed dose as soon as you remember. If it is almost time for the next scheduled dose, then the missed dose can be skipped. Do not double the dose to make up for the missed one.

Overdose

Contact your doctor immediately and seek emergency medical help in case of an overdose of this medicine.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Deflazacort

Antiviral vaccines and related products

Lidocaine

Doxorubicin

Ganciclovir

Methyl Prednisolone

Budesonide

Azathioprine

Cisplatin

Betamethasone

Clozapine

Linezolid

Tacrolimus

Hydrocortisone

Cyclosporine

Triamcinolone

Altretamine

Bleomycin

Daclizumab

Disease interactions

Infections

This medicine should be used with extreme caution in patients with a history of recurrent infections due to the increased risk of worsening of the patient’s condition. Initiation of therapy with this medicine in patients with active infections is not recommended. Patients susceptible to infections should be monitored closely during treatment with this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

Malignancies

This medicine should be used with extreme caution in patients with a history of malignancies. It should also be used with caution in patients who develop malignancies during treatment since it may worsen the patient's condition. These patients may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

Neurological disorders

This medicine should be used with caution in patients with an active neurological disorder since the risk of worsening of the patient's condition is significantly high. It is recommended to discontinue the use of this medicine if neurological disorders develop during the treatment course. An alternative treatment option should be considered in such cases based on the clinical condition.

Tuberculosis

This medicine should be used with extreme caution in patients who have previously been treated for latent or active tuberculosis. Anti-tuberculosis therapy should be initiated prior to therapy with this medicine if an active infection is confirmed. Appropriate tests should be conducted for the presence of latent tuberculosis in patients before initiating therapy with this medicine.

Congestive heart failure

This medicine should be used with caution in patients with congestive heart failure due to the increased risk of worsening of the patient’s condition. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

Bone Marrow Depression

This medicine should be used with caution in patients with bone marrow depression due to the increased risk of worsening of the patient’s condition. Blood component abnormalities should be considered before treatment with this medicine is initiated. You may require a dose adjustment and more frequent clinical monitoring to safely use this medicine. An alternative treatment option may be necessary in some cases based on the clinical condition.

Hepatitis B

This medicine should be used with caution in patients with a history of hepatitis B infection due to the increased risk of worsening of the patient’s condition. It is recommended to closely monitor patients with evidence of prior hepatitis B infection for signs and symptoms of reactivation. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition. If hepatitis B infection is reactivated, discontinuation of treatment with this medicine and initiation of antiviral therapy is recommended.
Food interactions
Information not available.
Lab interactions
Information not available.
It is advised to administer this medicine under the supervision of a doctor or a trained healthcare professional. Your dose regimen and frequency of administration is likely to vary based on the condition being treated. Consult your doctor immediately if you develop any signs and symptoms of an infection.
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by blocking the action of certain specific substances in the body that are responsible for causing inflammation (pain, swelling, redness, etc.) and other associated complications.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antirheumatics, TNF alfa inhibitors

Schedule

Schedule H

Adalimumab - DrugBank [Internet]. Drugbank.ca. 2018 [cited 28 August 2018]. Available from:

https://www.drugbank.ca/drugs/DB00051

[Internet]. Rxabbvie.com. 2018 [cited 28 August 2018]. Available from:

https://www.rxabbvie.com/pdf/humira.pdf

[Internet]. Accessdata.fda.gov. 2018 [cited 28 August 2018]. Available from:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf

DailyMed - Adalimumab injection, solution [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 28 August 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d

English |US [Internet]. Humira.com. 2018 [cited 28 August 2018]. Available from:

https://www.humira.com/

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 3 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.